复宏汉霖(02696.HK) 公布,HLX22(重组人源化抗HER2单克隆抗体注射液)联合曲妥珠单抗和化疗对比曲妥珠单抗和化疗联合或不联合帕博利珠单抗一线治疗HER2阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床试验申请于德国获批。
HLX22为公司许可引进并后续自主研发的新型靶向HER2的单克隆抗体,潜在适应症包括胃癌和乳腺癌等实体瘤。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.